Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2022 · 10-K
Revenue$50.38M$50.38M−10.7% vs Q4 2021 Net Income-$17.49M-$17.49MN/M vs Q4 2021 EPS Diluted-$0.86-$0.86N/M vs Q4 2021 Operating Incomederived-$20,099,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived$53,472,000+93.4% Free Cash Flowderived$51,341,000+101.8% Margins · derivedOperating margin-39.9%−106.7 pt vs Q4 2021
Net margin-34.7%−25.1 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 28, 2023 · 59 d after period end